AZ, Array BioPharma Add Trials for Anti-Cancer Drug

Array BioPharma and AstraZeneca plan to add two additional randomized Phase II trials for AZD6244 (ARRY-886). The trials, which will begin 2H08, will study AZD6244 in combination with a cytotoxic chemotherapeutic agent; one trial will be in melanoma patients and the other in non-small cell lung cancer patients. These plans are based on AZD6244’s activity as a single agent in previous monotherapy Phase II trials and preclinical data.
   
“We believe that AZD6244 holds promise for cancer patients and we look forward to the initiation of these additional Phase II trials,” said John Yates, M.D., chief medical officer of Array BioPharma. “We’re pleased to be working with AstraZeneca’s experienced oncology team and are excited about their strong commitment to bringing this novel treatment to people with cancer.”
   
AZ acquired exclusive worldwide rights to AZD6244 and certain second-generation compounds for all oncology indications in December 2003. Array was responsible for filing the IND and conducting the Phase I testing of AZD6244 and  AZ is responsible for all other aspects of clinical development and commercialization. Array retains the rights to all therapeutic indications outside of oncology for compounds not selected as part of the collaboration.